Lawood & Co’s Merck MRK Stock Holding History

Lawood & Co’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.99M	Sell	23,298 -145	-0.6%	-$17K	2.03%	14
2026 Q1	$2.82M	Sell	23,443 -1,015	-4%	-$117K	2.62%	11
2025 Q4	$2.57M	Buy	+24,458	New	+$2.3M	2.44%	12

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lawood & Co's MRK Position: Q2 2026 in Review

Lawood & Co reduced its Merck (MRK) stake by 0.62% in Q2 2026, selling an estimated $17K and leaving 23,298 shares worth $2.99M. The position accounts for 2.03% of the portfolio, ranked #14.

Lawood & Co first reported a position in MRK in Q4 2025 and has held it in 3 quarters since. 3,828 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Lawood & Co held 23,298 shares of Merck worth $2.99M as of Q2 2026.
Lawood & Co sold 145 Merck shares in Q2 2026, an estimated $17K.
Merck made up 2.03% of Lawood & Co's portfolio in Q2 2026, its #14 holding.
Lawood & Co first reported a position in Merck in Q4 2025 and has held it in 3 quarters since.
3,828 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Lawood & Co's 13F filing for Q2 2026, filed 13 Jul 2026.